Express Delivery
All orders are shipped with Speedy
Cash on delivery
Reliable and convenient payment methods
Proven quality
Peptides Tested at Janoshik Labs
Express delivery in 1-3 business days.
Each peptide comes with bacteriostatic water.
Tirzepatide is a synthetic peptide composed of 39 amino acids. The molecule belongs to the incretin analog group and exhibits dual activity on GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This combined receptor profile is precisely what distinguishes it from classic GLP-1 analogs, which primarily act on a single incretin pathway.
Initially, Tirzepatide was developed in the context of type 2 diabetes mellitus, but clinical trials have also described a significant effect on body weight reduction. In research models, changes in insulin sensitivity, blood sugar control, body composition, and a number of metabolic and cardiovascular parameters have been observed.
Tirzepatide is being investigated for its potential impact on several key metabolic areas:
Blood sugar control – research and clinical models have observed a reduction in HbA1c and a limitation of glucose spikes.
Weight reduction – an effect on reducing fat tissue and improving body composition has been described.
Metabolic health – changes in lipid profile, hepatic steatosis, and other markers associated with metabolic risk have been observed.
Cardiovascular function – reductions in blood pressure and triglycerides have been described in research settings.
Energy homeostasis – an effect on appetite, energy balance, fat oxidation, and metabolic regulation has been observed.
Tirzepatide has been the subject of extensive clinical trials, in which it has emerged as an incretin analog with a pronounced effect on glycemic control and body weight.
In patients with type 2 diabetes mellitus, the following has been reported:
- HbA1c reduction by up to 2%
- Weight loss of 10-15%
- Improvement in lipid profile and blood pressure
In people with obesity without diabetes, the following has been observed:
- Weight loss of up to 20% over 72 weeks
- Reduction of visceral fat
- Improvement in cardio-metabolic parameters
Scientific literature describes once-weekly subcutaneous administration within clinical and research protocols.
Standard doses: 2.5 mg - initial dose with gradual titration up to 5 mg weekly depending on tolerance and therapeutic effect.
For 5 mg + 2 ml bacteriostatic water:
Concentration = 2.5 mg/ml → 0.4 ml = 1 mg
Example values for 5 mg:
0.1 ml = 250μg
0.2 ml = 500μg
0.3 ml = 750μg
0.4 ml = 1 mg
0.5 ml = 1.25 mg
For 10 mg + 2 ml bacteriostatic water:
Concentration = 5 mg/ml → 0.2 ml = 1 mg
Example values for 10 mg:
0.1 ml = 500μg
0.2 ml = 1 mg
0.3 ml = 1.5 mg
0.4 ml = 2 mg
0.5 ml = 2.5 mg
The most commonly reported reactions in clinical and research data are related to the gastrointestinal tract, especially during periods of dose escalation.
Possible side effects are highly dose-dependent and include:
- nausea, vomiting, diarrhea, constipation
- decreased appetite
- abdominal discomfort
Rarer but more serious risks include:
- pancreatitis
- gallstone disease with rapid weight reduction
- hypoglycemia when combined with other antidiabetic agents
The information is collected and systematized from various scientific sources and studies. It is for educational purposes only and should not be used for diagnosis, treatment, or prevention of diseases.